CRISPR Therapeutics
CRSP
52.35
-1.65
-3.06%
CRISPR Therapeutics
US · CRSP
#2057 by market cap
Listed 2016
52.35
-1.65
-3.06%
Live - 5344 symbols - heartbeat 494s ago
· 2026-10-08 08:20
Pre-market
51.53
-1.57%
After-hours
52.65
+0.57%
Overnight
52.09
-0.50%
- Market cap
- 5.06B
- P/E (TTM)i
- -11.11
- P/Bi
- 2.90
- EPSi
- -6.47
- Div yieldi
- 0.00%
- 52W posi
- 27%
Reader sentiment
Are you bullish or bearish on CRSP?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 12 analysts
Buy
Avg price target
76.18 +45.5%
Price target rangecurrent 52.35
Low50.00
Avg76.18
High110.00
Buy 67%
Hold 33%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-05 | Needham | -- | BUY | 82.00 |
| 2026-10-02 | Wells Fargo | -- | HOLD | 75.00 |
| 2026-09-04 | Citi | -- | BUY | 88.00 |
| 2026-08-31 | Evercore | -- | BUY | 76.00 |
| 2026-08-31 | Needham | -- | BUY | 82.00 |
| 2026-08-31 | H.C. Wainwright | -- | BUY | 80.00 |
| 2026-08-28 | William Blair | -- | BUY | -- |
| 2026-08-28 | Morgan Stanley | -- | HOLD | 60.00 |
| 2026-08-10 | Goldman Sachs | -- | HOLD | 55.00 |
| 2026-08-07 | Goldman Sachs | -- | HOLD | 55.00 |
| 2026-08-06 | Goldman Sachs | -- | HOLD | 55.00 |
| 2026-08-05 | Wells Fargo | -- | HOLD | 75.00 |
| 2026-08-05 | BofA Securities | -- | BUY | 82.00 |
| 2026-08-05 | H.C. Wainwright | -- | BUY | 80.00 |
| 2026-08-04 | William Blair | -- | BUY | -- |
| 2026-08-04 | Piper Sandler | -- | BUY | 110.00 |
| 2026-08-04 | Morgan Stanley | -- | HOLD | 60.00 |
| 2026-08-04 | Needham | -- | BUY | 82.00 |
| 2026-08-03 | Citi | -- | BUY | 88.00 |
| 2026-08-03 | RBC Capital | -- | HOLD | 50.00 |
| 2026-07-22 | Citizens JMP | -- | BUY | 80.00 |
| 2026-07-08 | H.C. Wainwright | -- | BUY | 80.00 |
| 2026-07-07 | BofA Securities | -- | BUY | 83.00 |
| 2026-07-02 | Piper Sandler | -- | BUY | 110.00 |
| 2026-06-24 | Needham | -- | BUY | 82.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Morgan Stanley moved from Sell to Hold on 2026-08-04.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-08-04 | Morgan Stanley | SELL → HOLD | 60.00 |
Quote time 2026-10-08 08:20:18 · For reference only, not investment advice and not tailored to your situation.